Author's response to reviews

Title: Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy.

Authors:

Shiro Fujita (jp.shirofujita@gmail.com)
Katsuhiro Masago (masago@kuhp.kyoto-u.ac.jp)
Yukimasa Hatachi (yukimasa@kuhp.kyoto-u.ac.jp)
Akiko Fukuhara (afuku53@kuhp.kyoto-u.ac.jp)
Akito Hata (a-hata@fbri.org)
Reiko Kaji (naya@fbri.org)
Young Hak Kim (ekim@kuhp.kyoto-u.ac.jp)
Tadashi Mio (mio@kuhp.kyoto-u.ac.jp)
Michiaki Mishima (mishima@kuhp.kyoto-u.ac.jp)
Nobuyuki Katakami (katakami@fbri.org)

Version: 2 Date: 8 September 2010

Author's response to reviews:

Dear Dr. Edmunds,

We are uploading the revised manuscript entitled, “Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy <MS: 2129450925379945>,” which we wish to submit for publication in the BMC Medical Genetics.

This manuscript contains novel observations concerning endothelial nitric oxide (eNOS) gene polymorphism and the survival of patients with advanced non-small-cell lung cancer. Nitric oxide is a free radical that is involved in various physiologic and pathophysiologic processes, including vasodilation, neuronal transmission, immunity and carcinogenesis. eNOS polymorphisms have been associated with an increased incidence of several malignancies, but its significance in patients’ survival has yet to be clearly defined. In this manuscript, we demonstrate that the variable number of tandem repeats polymorphism in eNOS intron 4 is an independent prognostic factor for survival in patients with advanced stage non-small-cell lung cancer.

We are most grateful to you and the reviewers for the helpful comments on the original version of our manuscript. We have taken all these comments into account and submit a revised version of our paper. We have addressed all the comments by reviewers, as indicated below, and we hope that our explanations and revisions are satisfactory.

We hope that the revised version of our paper is now suitable for publication in
the BMC Medical Genetics and we look forward to hearing from you at your earliest convenience.

Yours sincerely,
Shiro Fujita, M.D., Ph.D.